Home › Oligodendroglioma › Ohio
Oligodendroglioma clinical trials in Ohio
4 studies for Oligodendroglioma are looking for participants at sites in Ohio.
Cities in Ohio
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07703436Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
- University Hospitals Cleveland Medical Center, Cleveland
Recruiting
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07628647SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Study of Olutasidenib and Temozolomide in HGG
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.